Why the study?
HFrEF and MASLD are both associated with liver fibrosis, but the association of FIB-4 score with mortality and liver outcomes in HFrEF required examination.
Does a high FIB-4 score predict increased mortality and major adverse liver outcomes in patients with HFrEF?
Population
4523 HFrEF patients from the Danish Heart Failure Registry
Comparison
High-risk vs indeterminate-risk vs low-risk FIB-4 score groups
Design
Registry-based cohort study
Follow-up
Five years
Key result
A high FIB-4 score in patients with HFrEF was associated with a higher 5-year incidence of all-cause mortality compared to a low score (43% vs 23%; HR 1.51, 95% CI 1.31-1.74).
Authors
Loading...
High FIB-4 may stratify mortality risk in HFrEF; hypothesis-generating and requires prospective validation before clinical use.
Cohort (n=4,523)
Yes
Does a high FIB-4 score predict increased mortality and major adverse liver outcomes in patients with HFrEF?
Hazard Ratio: 1.51 (95% CI 1.31–1.74)
Absolute Event Rate: 43% vs 23%
A high FIB-4 score in patients with HFrEF is a significant prognostic marker associated with increased all-cause mortality, cardiovascular mortality, and major adverse liver outcomes.
Mohamed et al. (2025) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=4,523). High FIB-4 score vs. Low FIB-4 score was evaluated on all-cause mortality (HR 1.51, 95% CI 1.31-1.74). A high FIB-4 score in patients with HFrEF was associated with a higher 5-year incidence of all-cause mortality compared to a low score (43% vs 23%; HR 1.51, 95% CI 1.31-1.74).